Energy Metabolites as Biomarkers in Ischemic and Dilated Cardiomyopathy

With more than 25 million people affected, heart failure (HF) is a global threat. As energy production pathways are known to play pivotal role in HF, we sought here identify key metabolic changes ischemic- and non-ischemic HF by using multi-OMICS approach. Serum metabolites mRNAseq epigenetic DNA methylation profiles were analyzed from blood left ventricular biopsy specimens of the same individuals. In total collected serum n = 82 patients with Dilated Cardiomyopathy (DCM) 51 controls screening stage. We identified several involved glycolysis citric acid cycle be elevated up 5.7-fold DCM (p 1.7 × 10?6). Interestingly, cardiac mRNA genes encoding rate-limiting enzymes these could also found validated our second stage metabolite assessment 52 DCM, 39 ischemic 57 controls. conclusion, new set metabolomic biomarkers for HF. able underlying biological cascades that potentially represent suitable intervention targets.